When hospitals overcharge insurers for drugs they bought at deep 340B discounts, taxpayers, employers, and insured patients foot the bill.

This contributor column discusses a recent study that shows the 340B Program’s explosive growth is overwhelmingly due to utilization increases, not price. Payers have struggled with the increasing ...

The 340B Drug Pricing Program was designed to help safety net providers serve low-income patients, but it has since ballooned into a multibillion-dollar system dominated by large health systems — with ...

With post-pandemic Medicaid enrollments on the decline and expected to fall further, revenue cycle leaders warn that ...

On January 7, 2026, the First Circuit Court of Appeals denied the federal government’s emergency motion to stay a district court injunction blocking implementation of HRSA’s 340B Rebate Model Pilot ...

On July 31, 2025, the Health Resources and Services Administration (HRSA) released long-awaited guidance establishing a 340B Rebate Model Pilot Program (Pilot Program). The announcement marks a ...

Even as they sparred on broader healthcare policy and funding topics fueling the ongoing government shutdown, senators of the Health, Education, Labor and Pensions Committee appear to agree that ...

Nevada hospitals and clinics face challenges as drug manufacturers restrict access to a federal discount drug program, ...

The Patient Protection and Affordable Care Act is expected to bring significant change to the healthcare industry, including the expansion of the Public Health Service Act Section 340B Program.

The 340B drug discount program would work better if the money followed the patient rather than going directly to hospitals, Anthony DiGiorgio, DO, MHA, said Monday at an event on 340B sponsored by the ...